2012 Agenda
Second International Conference on Cancer and the Heart
November 9-10, 2012
Conference Location:
MD Anderson Cancer Center
Cancer Prevention Building (CPB)
1155 Pressler Street, Floor 8
Houston, Texas 77030
PRELIMINARY AGENDA
Friday, November 9, 2012 |
| 7:00 a.m | Registration and continental breakfast |
Overview
| Edward T.H. Yeh, M.D. Chair, Cardiology The University of Texas MD Anderson Cancer Center Houston, TX |
Welcome
| Ronald A. DePinho, M.D., President MD Anderson Cancer Center Houston, TX |
| Session I 8:15-8:30 a.m. | The Collaboration between Oncology and Cardiology Moderator: Edward T.H. Yeh, M.D. Chair, Cardiology The University of Texas MD Anderson Cancer Center Houston, TX |
| ASCO Sandra Swain, M.D. President, ASCO Medical Director, Washington Cancer Institute Washington, D.C. | |
| ACC William A. Zoghbi, M.D. President, American College of Cardiology The Methodist DeBakey Heart & Vascular Center Houston, TX | |
| Session II 8:30-9:30 a.m. | Advances in Cardiology and Oncology Moderator: Edward T.H. Yeh, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
8:30-9:00 a.m.
| MicroRNA control of cardiac disease and repair Eric Olson, Ph.D. UT Southwestern Medical Center at Dallas Dallas, TX |
9:00-9:30 a.m.
| Changing landscape of cancer research and care Edward J. Benz, Jr., M.D. President and CEO Dana-Farber Cancer Institute Boston, MA |
| Break | 9:30-9:50 a.m. |
| Session III 9:50-10:55 a.m. | Anthracycline-induced cardiotoxicity Moderator: Gabriel N. Hortobagyi, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
9:50-10:15 a.m.
| Molecular basis of Doxorubicin-induced cardiotoxicity Edward T.H. Yeh, M.D. Chair, Cardiology The University of Texas MD Anderson Cancer Center Houston, TX |
10:15-10:35 a.m.
| The evolving role of anthracyclines in the treatment of breast cancer Gabriel N. Hortobagyi, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 10:35-10:55 a.m. | Panel discussion Robert S. Benjamin, M.D. Chair, Sarcoma Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX Steven Lipshultz, M.D. University of Miami Miller School of Medicine Miami, FL Edward T.H. Yeh, M.D. Chair, Cardiology The University of Texas MD Anderson Cancer Center Houston, TX |
| Session IV 10:55-11:40 a.m. | Herceptin-induced cardiotoxicity Moderator: Vincent Valero, M.D. Professor and Chair Ad Interim Breast Medical Oncology The University of Texas M. D. Anderson Cancer Center Houston, TX |
10:55-11:25 a.m.
| Cardiotoxicity with HER2 targeted therapy Sandra Swain, M.D. President, ASCO Medical Director, Washington Cancer Institute Washington, D.C. |
11:25-11:40 a.m.
| Trastuzumab: Guilty or guilty by association Michael Ewer, M.D., J.D., M.P.H. The University of Texas MD Anderson Cancer Center Houston, TX |
| Lunch | 11:40-12:55 p.m |
| Session V 12:00-12:35 p.m. | Onco-cardiology services |
12:00-12:05 p.m.
| Introduction Robert F. Gagel, M.D. Division Head, Division of Internal Medicine The University of Texas MD Anderson Cancer Center Houston, TX |
| 12:05-12:35 p.m. | Moderator: Richard Steingart, M.D. Memorial Sloan-Kettering Cancer Center New York, NY |
| Ana Barac, M.D., Ph.D. Medstar Heart Institute Washington Cancer Institute Washington, D.C. | |
| Steven M. Ewer, M.D. School Of Medicine and Public Health University Of Wisconsin-Madison Madison, WI | |
| Kerry Russell, M.D., Ph.D. Yale University Medical School New Haven, CT | |
| Edward T.H. Yeh, M.D. Chair, Cardiology The University of Texas MD Anderson Cancer Center Houston, TX | |
| 12:35-12:55 | Break |
| Session VI 12:55-1:35 p.m. | Basic mechanisms Moderator: Raymond Russell, M.D., Ph.D. Yale University Medical School New Haven, CT |
12:55-1:15 p.m.
| Chemical biology approaches to chemotherapy cardiotoxicity: Fighting fire with fire Jay Schneider, M.D., Ph.D. UT Southwestern Medical Center at Dallas Dallas, TX |
1:15-1:35 p.m.
| Chemotherapy and cardiomyocyte autophagy Joseph A. Hill, M.D., Ph.D. UT Southwestern Medical Center at Dallas Dallas, TX |
| Session VII 1:35-2:25 p.m. | Cardiotoxicity in pediatric populations Moderator: Joann L Ater, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
1:35-2:00 p.m.
| Childhood cancer cardiovascular toxicity Steven E. Lipshultz, M.D. University of Miami Miller School of Medicine Miami, FL |
2:00-2:15 p.m.
| Cardiotoxicity in aging adult survivors of childhood cancer Gregory T. Armstrong, M.D., M.S.C.E. St. Jude Children's Research Hospital Memphis, TN |
| 2:15-2:25 p.m. | Questions and answers |
| Break | 2:25-2:45 p.m. |
| Session VIII 2:45-3:30 p.m. | Early identification of patients with heart failure: Biomarkers Moderator: Michael Fisch, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
2:45-3:05 p.m.
| Evolution of biomarkers in detecting early cardiac damage Daniela Cardinale, M.D., Ph.D. European Institute of Oncology Milano, Italy |
3:05-3:20 p.m.
| PREDICT study Daniel Lenihan, M.D. Vanderbilt University Medical Center Nashville, TN |
| 3:20-3:30 p.m. | Questions and answers |
| Session IX 3:30-5:00 p.m. | Early identification of patients with heart failure: Echo and MRI Moderator: Jose Banchs, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
3:30-3:55 p.m.
| Early identification of patients with cardiac complications of chemotherapy Thomas Marwick, M.D., Ph.D., M.P.H. Menzies Research Institute of Tasmania Hobart, Australia |
3:55-4:20 p.m.
| Cardiovascular injury upon receipt of chemotherapy- New insights from magnetic resonance imaging W. Gregory Hundley, M.D. Wake Forest University Baptist Medical Center Winston-Salem, NC |
| 4:20-4:35 p.m. | Advanced echocardiography in the evaluation of chemotherapy patients Juan Carlos Plana, M.D. Cleveland Clinic Cleveland, OH |
| 4:35-4:45 p.m | Case presentation Jose Banchs, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 4:45-5:00 p.m. | Questions and answers |
| Session X 5:00-6:00 p.m. | Poster Session: Beer, Wine, and Hors D'oeurves |
Saturday, November 10, 2012 |
| 7:00 a.m | Registration and continental breakfast |
| Session XI 8:00-8:45 a.m. | Radiation Moderator: S. Wamique Yusuf, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
8:00-8:10 a.m.
| Case presentation S. Wamique Yusuf, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
8:10-8:35 a.m.
| Radiation-related heart disease: How big are the risks? Sarah Darby, Ph.D. University of Oxford Oxford, United Kingdom |
| 8:35-8:45 a.m. | Questions and answers |
| Session XII 8:45-10:05 a.m. | Cardiotoxicity of TKIs Moderator: Edward T.H. Yeh, M.D. Cardiology The University of Texas MD Anderson Cancer Center Houston, TX |
8:45-9:05 a.m. | Why is preclinical prediction of cardiotoxicity so bad? Thomas Force, M.D. Temple University School of Medicine Philadelphia, PA |
9:05-9:20 a.m.
| Tyrosine Kinase Inhibitors Related Cardiotoxicity: Is there a role for routine cardiac monitoring? Elie Mouhayar, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
9:20-9:40 a.m.
| Cardiotoxicities of novel angiogenesis (VEGF) inhibitors Javid Moslehi, M.D. Dana-Farber Cancer Institute Boston, MA |
9:40-9:55 a.m.
| Gleevec: Selective vs. non-selective TKIs in cardiotoxicity Jean-Bernard Durand, M.D. The University of Texas MD Anderson Cancer Center Houston, TX Thomas Force, M.D. Temple University School of Medicine Philadelphia, PA |
9:55-10:05 a.m.
| Case presentation: Dasatinib and pulmonary hypertension Saamir Hassan, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| Break | 10:05-10:25 a.m. |
| Session XIII 10:25-10:45 | Link between cancer and heart disease: Story of HACE1 and E3 ligase Peter Liu, M.D. Ph.D. University of Ottawa Heart Institute Ottawa, Ontario, Canada |
| Session XIV 10:45-11:05 a.m. | Cardiac Tumors: Moderator: Jean-Bernard Durand, M.D. Cardiac Tumors – Diagnosis and Therapy Monika Leja, M.D. University of Michigan Ann Arbor, MI |
| Session XV 11:05-12:15 a.m. | Clinical Cardiovascular Challenges in a Cancer Center Moderator: Elie Mouhayar, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 11:05-11:20 p.m. | Pericardial Effusion Elie Mouhayar, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 11:20-11:35 a.m. | Acute Cardiomyopathy Jean-Bernard Durand, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 11:35-11:45 a.m. | Radiation and Cardiovascular Implantable Electronic Device Kaveh Karimzadehnajar, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 11:45-12:00 p.m. | QT Prolongation and QT induced torsades Michael Ewer, M.D., J.D., M.P.H and Peter Kim, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 12:00-12:15 p.m. | Questions & Answers |
| Lunch | 12:15-1:00 p.m. |
| Session XVI 1:00-2:00 p.m | Medical treatment of heart failure Moderator: Barbara Summers, Ph.D., M.S.N. Vice President and Chief Nursing Officer The University of Texas MD Anderson Cancer Center Houston, TX |
1:00-1:15 p.m.
| Treatment of cancer therapy-induced heart failure Jean-Bernard Durand, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
1:15-1:30 p.m.
| Heart failure in cancer patients: Management through onco-cardiology collaborative Anecita Fadol, Ph.D., M.S.N. The University of Texas MD Anderson Cancer Center Houston, TX |
1:30-1:45 p.m.
| Early diastolic dysfunction precursor to LVEF decline Giorgio Minotti, M.D. University Campus Bio-Medico Rome, Italy |
| 1:45-2:00 p.m. | Questions and Answers |
| Session XVII 2:00-2:30 p.m. | Intervention in cancer patients Moderator: Saamir Hassan, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 2:00-2:15 p.m. | Optical coherence tomography Cezar Iliescu, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| 2:15-2:30 p.m. | Interventional procedures in thrombocytopenic patients Cezar Iliescu, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
| Session XVIII 2:30-3:00 p.m. | Advanced heart failure treatment Moderator: Cezar Iliescu, M.D. The University of Texas MD Anderson Cancer Center Houston, TX |
2:30-2:45 p.m.
| Advanced heart failure treatment for aging cancer survivors Igor Gregoric, M.D. University of Texas Health Science Center Houston, Texas |
2:45-3:00 p.m.
| Questions and Answers Jean-Bernard Durand, M.D. The University of Texas MD Anderson Cancer Center Houston, TX Igor Gregoric, M.D. University of Texas Health Science Center Houston, Texas Guilherme Oliveira, M.D. Cleveland Clinic Cleveland, OH |
| Session XIX 3:00-3:50 p.m. | Clinical trials & research considerations Moderator: Giorgio Minotti, M.D. University Campus Bio-Medico Rome, Italy |
3:00-3:15 p.m.
| Assessment of cardiotoxicity and optimization of cardiac screening in Phase I clinical trials Apostolia-Maria Tsimberidou, M.D., Ph.D. The University of Texas M. D. Anderson Cancer Center Houston, TX |
3:15-3:30 p.m.
| Practice Strategies Joseph Carver, M.D. Abramson Cancer Center, University of Pennsylvania Philadelphia, PA |
3:30-3:50 p.m.
| Panel discussion Giorgio Minotti, M.D. Joseph Carver, M.D. Daniela Cardinale, M.D. Ph.D. Jean-Bernard Durand, M.D. Apostolia-Maria Tsimberidou, M.D., Ph.D. |
| Adjourn | 3:50 p.m. |
14.25 AMA PRA Category 1 Credits™
The University of Texas MD Anderson Cancer Center is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Nursing contact hours will be awarded. Up to 13.50 contact hours for full attendance at all sessions.
For information contact Amy Heaton: aheaton@mdanderson.org or 713-745-6826.
Late Breaking News
Key discovered to how chemotherapy drug causes heart failure. See News Release
Endorsed By
